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Fair allocation of organs to candidates listed for transplantation is fundamental to organ-donation policies. Processes leading to
listing decisions are neither regulated nor understood. We explored whether patient characteristics aﬀected timeliness of listing
using population-based data on 144,507 adults hospitalized with liver-related disease in Pennsylvania. We linked hospitalizations
to other secondary data and found 3,071 listed for transplants, 1,537 received transplants, and 57,020 died. Among candidates,
61% (n = 1,879) and 85.5% (n = 2,626) were listed within 1 and 3 years of diagnosis; 26.7% (n = 1,130) and 95% (n = 1,468)
of recipients were transplanted within 1 and 3 years of listing. Using competing-risks models, we found few overall diﬀerences by
sex, but both black patients and those insured by Medicare and Medicaid (combined) waited longer before being listed. Patients
with combined Medicare and Medicaid insurance, as well as those with Medicaid alone, were also more likely to die without ever
being listed. Once listed, the time to transplant was slightly longer for women, but it did not diﬀer by race/ethnicity or insurance.
The early time period from diagnosis to listing for liver transplantation reveals unwanted variation related to demographics that
jeopardizes overall fairness of organ allocation and needs to be further explored.
1.Introduction
Because the demand for transplant services has always
exceeded the supply of donor organs, the transplant com-
munity as well as policymakers have long recognized the
need to ensure that the organ allocation system is eﬃcient
and equitable [1–6]. The United Network for Organ Sharing
(UNOS),which overseeswaitlistingandallocationguidelines
in the United States, indicates that access to organs will not
be based on “political inﬂuence, race, gender, religion, or
ﬁnancial or social status” [7]. Yet, as noted by the Institute
of Medicine, the transplant process involves numerous steps
and inequities can take place anywhere along the way [8].
Historically, in cases where empirical data have shown
systematic diﬀerences in waiting times or in the chances of
receiving a transplant, UNOS has changed its policies to
improve organ allocation procedures. Examples of changes
include the institution of less stringent HLA-matching
requirements for renal transplantation [9], the adoption of
t h eﬁ n a lr u l e[ 6], and the use of the model of end-stage
liverdisease (MELD) scoring system forlivertransplantation
[10, 11]. For renal transplantation, researchers have access to
population-based data about the early steps of the transplant
process from the US Renal Data System [12–14]. But
for other types of solid organ transplantation, including
liver transplantation, information about the early steps is2 Journal of Transplantation
generally unavailable, so oversight is restricted to steps after
listing.
We linked several secondary data sources to identify a
statewide, population-based cohort of patients with liver-
related conditions and followed the cohort through the
following stages of the transplant process: disease occurrence
(incidence), disease progression (natural history), disease
diagnosis, referral, and evaluation by a transplant center,
placement on the transplant waiting list (listing), and receipt
of an organ (transplantation). We previously reported that
demographics were important in determining the likelihood
that patients with liver disease would be able to access
the transplantation process for evaluation and listing, but
not in aﬀecting the likelihood that they would undergo
transplantation once they were listed [15]. This initial
analysis evaluated only whether or not patients progressed
to speciﬁc stages of the transplantation process; because of
missing data, it did not address matters related to timing and
timeliness.
In the current paper, we estimated the relationship
between sociodemographics and the time required for
patientstoreachspeciﬁcstagesoftheprocess.Speciﬁcally,we
examined waiting times experienced by subsets of patients
during 2 time periods. The subsets were based on gender,
race/ethnicity,and insurance status. Oneperiod was thetime
between a patient’s diagnosis of liver disease and his or her
placement on the UNOS waiting list (an interval in which
there is no formal oversight or centralized data collection
eﬀort),and the other period was the time between a patient’s
placement on the UNOS waiting list and his or her receipt
of a transplant (an interval in which there is oversight).
Our main hypothesis was that gender, race/ethnicity, and
insurance status would be associated with variation in wait-
ing times before, but not after, placement on the transplant
waiting list.
2.Methods
2.1. Data Sources and Data Management. Our conceptual
framework, data sources, and patient cohort have been
described previously [15]. Brieﬂy, we considered the stages
in which a patient developed liver disease, was diagnosed,
was referred to a transplant center and evaluated, was listed,
and received a transplant. We assumed that most individuals
who become suﬃciently ill to be considered for a transplant
werehospitalizedatsomepointintheirillness and,therefore,
used hospital discharge data from the Pennsylvania Health
Care Cost Containment Council (PHC4) to identify patients
who had “liver-transplant potential.” Every nongovernment
hospital in Pennsylvania is required by state law to submit
clinically abstracted data to the PHC4 for all hospital
discharges, and the accuracy of the data has been validated
against chart reviews [16].
The PHC4 listed 310 participating hospitals statewide
during the study period. It provided us with data for all
patients with liver-related stays between 1994 and 2001.
These data included the patients’ age, gender, race/ethnicity,
and county and ZIP code of residence, type of admis-
sion, admission and discharge diagnoses, procedures, and
diagnosis-related group (DRG) codes, discharge destination,
and Medical Illness Severity Grouping System (MEDIS-
GRPS) disease category (mortality risk) and severity score.
To help identify and classify patients with liver disease, we
developed a detailed list of diagnostic and procedural codes
related to liver problems. Based on our previous work [17],
we classiﬁed patients in terms of 9 major categories of
disease: viral hepatitis, alcoholic liver disease, autoimmune
disorder, metabolic disease, primary sclerosing cholangitis,
cancer, primary biliary cirrhosis, other chronic liver disease,
and acute liver failure.
We excluded patients who were discharged in 1994 as
well as those who had previously received a liver-transplant
or been listed for one. This left us with a cohort of 144,507
patients with liver disease from 272 hospitals that had
been newly diagnosed between 1995 and 2001. We linked
the index hospitalization records of these patients to the
following: the liver referral and evaluation data from the 5
predominant liver-transplant centersinPennsylvania (Albert
Einstein Medical Center, Hospital University of Pennsyl-
vania, Thomas Jeﬀerson University Hospital, University of
PittsburghMedicalCenter,andtheVAPittsburghHealthcare
System), the listing, allocation, and transplant data from
UNOS, and the mortality data from the Bureau of Health
Statistics and Research of the Pennsylvania Department of
Health.
For many patients in these data sets, the speciﬁc time
at which some stages were reached was missing. However,
t h ed a t aw e r ec o m p l e t ef o rt h et i m eo fd i s e a s ed i a g n o s i s ,
waitlisting, and transplantation. This allowed us to deter-
mine whether patients progressed to a subsequent stage and
to measure the time intervals, in days, from diagnosis to
listing (early waiting time) and from listing to receipt of a
transplant (later waiting time). In each case, there were 3
possible outcomes: proceed to the subsequent stage of the
process, remain at the current stage, or die.
Theunitofanalysis was thepatient(nottheregistration).
Although the data were deidentiﬁed by the honest broker,
multiple listings could be identiﬁed and reconciled using
a pseudoidentiﬁer for patients. We combined the dates
from all of the data sources to “timestamp” the patient’s
progression through the transplantation process, starting
with index hospitalization (i.e., diagnosis) until either the
earliest deﬁnitive outcome(i.e., transplant, death) or the end
of the study period (i.e., still waiting).
In pooling the data sources, we applied 2 strategies for
creatingthelongitudinalrecordsforourpatientcohort.First,
we did not adjust the waiting times to account for periods
when the patient was inactive (a special status category for
patients on the waiting list), which increases the estimates of
later waiting times from listing to transplantation. Second,
for patients with multiple listings, we took the earliest listing
date available. Both of these conventions minimize early
waiting time from diagnosis until listing and maximize later
waiting times from listing to transplant, serving to bias
against our hypothesis that early waiting times vary with
socioeconomic variables (but later waiting times do not).
Our study was funded by the National Institute of
Diabetesand Digestiveand KidneyDiseasesand approvedbyJournal of Transplantation 3
theinstitutionalreviewboardsattheUniversityofPittsburgh
and other participating transplant centers. We protected
patientconﬁdentialitybyhavingthePHC4serveasanhonest
broker to link records across data sources and provide our
team with deidentiﬁed versions of the ﬁles.
2.2. Statistical Analyses. To characterize patients in terms of
sociodemographic and clinical data, stage of the allocation
process (diagnosis, listing, and receipt of a transplant),
waiting times, and outcomes, we used descriptive statistics.
To compare the characteristics of subsets of patients
at each stage of the process, we used univariable and
multivariable survival models that included the following
covariates: age, gender, race/ethnicity (white, black, His-
panic/Asian/other, and unknown), insurance status (com-
mercial only, Medicaidonly, Medicare only, combinedMedi-
care plus commercial, combined Medicare plus Medicaid,
uninsured, and unknown) based on the index hospitaliza-
tion, type of liver disease using the diagnostic categories
listed above, and severity of illness at the time of diagnosis,
based on the MediQual severity scale [18] and ranging from
0 to 4 (representing none, minimal, moderate, severe, or
maximal) or coded as unknown. Given our focus on state-
level data, there was no variation in terms of geographic
region, but we did include location of transplant center
(Pennsylvania versus non-Pennsylvania) as a covariate in the
modelstoaccountforPennsylvania residentswho were listed
and/or transplanted at other centers. We included year of
index hospitalization and also tested for interaction variables
(e.g., interaction between diagnosis and gender).
In the unadjusted case, we looked at diﬀerences in
early waiting times based on the proportion of diagnosed
patients who were placed on the transplantation waiting list
within a speciﬁed period (i.e., 1, 3, 5, and 8 years) using
Kalbﬂeisch and Prentice’s cumulative incidence technique
[19]. Similarly, we looked at diﬀerences in later waiting
times by examining the proportion of listed patients who
received transplants at these same intervals. In both cases, we
controlled for the competing risk of death.
In the adjusted models, we tested for diﬀerences in
early waiting times by estimating the time to listing for the
entire cohort, and we tested for diﬀerences in later waiting
times by estimating time to transplant for patients on the
waiting list. We used Fine and Gray’s survival model that
takes death and other competing risks into account [20]. We
compared diﬀerences in the magnitude and signiﬁcance of
ourprimarycovariates(gender,race/ethnicity,andinsurance
status) while adjusting for the other covariates.
We retained all covariates with P<. 0 5 ,a n dw eu s e dS A S ,
version9.2(SASInstituteInc.,Cary,NC)andSTATA,version
8 (Stata Corp., College Station, TX) for all analyses.
3.Results
Table 1 shows data for 3 groups—the full cohort, the subset
of patients listed for transplantation, and the ﬁnal subset
of patients who received transplants—stratiﬁed by sociode-
mographic and clinical characteristics. In all 3 groups, the
largestproportionsofpatientsweremale,were40–64yearsof
age, had commercial health insurance only, had a diagnosis
of viral hepatitis, alcoholic liver disease, or autoimmune
disorder, and had a moderate or severe level of illness.
Because of the large sample size, between-group diﬀerences
were statistically signiﬁcant for all covariates. In general,
however, diﬀerences between the ﬁrst and second groups
(full cohort and listed patients) were larger than diﬀerences
between the second and third groups (listed patients and
transplant recipients).
Of the 144,507 adults in our ﬁnal cohort of patients
with liver-transplant potential, 3,071 (2.1%) were placed on
the transplant waiting list. Of these 3,071 patients, 1,537
(50.0%) went on to receive a liver transplant by December
2003. Based on raw waiting times, 61% (n = 1,879) of all
transplant candidates were placed on the waiting list within
1 year of diagnosis, and 85.5% (n = 2,626) were listed
within 3 years of diagnosis. Among transplant recipients,
26.7% (n = 1,130) received transplants within 1 year of
listing and 95% (n = 1,468) received transplants within 3
yearsoflisting.Atotalof57,020patients(39.5%)diedduring
the study period.
3.1. Univariable Analyses. Because waiting times are cen-
soredforpatientswhodonotprogresstothenextstageofthe
process(e.g.,diagnosedpatientswhoarenotlisted,andlisted
patientswho do not receive transplants), mean waiting times
cannot be computed. Instead, Table 2 reports the cumulative
percentageofpatientswho progressed tothenext stageofthe
transplantation process within speciﬁc time intervals, ﬁrst
among diagnosed patients and then among listed patients, as
well as the cumulative percentage of patients who died (the
competing risk) during those same intervals.
Among the 144,507 diagnosed patients in the cohort,
1.3% were listed within 1 year of the index hospitalization
and 2.1% were listed within the 8-year study period (Table 2,
top panel). During the same period, 21.9% of the patients
died within 1 year and 38.6% died within 8 years. In the
stratiﬁed results, women diagnosed with liver disease were
less likely than their male counterparts to be listed but
were also less likely to die. At every interval, black patients
had lower probabilities of being listed, and patients in the
Hispanic/Asian/other category had lower probabilities of
death than the overall cohort did. In terms of insurance
status, patients with commercial insurance were more likely
to be listed and less likely to die whereas patients with any
form of Medicare insurance coverage exhibited the opposite
pattern and were less likely to be listed and more likely to die
than the overall cohort.
For later waiting times after listing (until transplanta-
tion) (Table 2, bottom panel), women continued to receive
transplants at lower rates than men and had greater risks
of dying on the waiting list. Black patients showed the
same pattern, with fewer transplants and more deaths than
white patients.BoththeMedicarepatientsandtheuninsured
patients (including self-pay patients) were listed at higher-
than-average rates, but the Medicare patients had higher-
than-average risks of death while the uninsured patients had
lower-than-average risks of death.4 Journal of Transplantation
Table 1: Characteristics of patients with liver-transplant potential∗.
Full cohort of patients Patients who were listed for a transplant Patients who received a transplant
Characteristic, no. (%) N = 144,507 n = 3,071 n = 1,537
Age
18–39 years 25,779 (17.8) 493 (16.1) 225 (14.6)
40–64 years 60,856 (42.1) 2,365 (77.0) 1,219 (79.3)
≥65 years 57,872 (40.1) 213 (6.9) 93 (6.1)
Gender
Male 77,885 (53.9) 1,880 (61.2) 987 (64.2)
Female 66,622 (46.1) 1,191 (38.8) 550 (35.8)
Race/ethnicity
White 103,969 (72.0) 2,267 (73.8) 1,165 (75.8)
Black 19,791 (13.7) 260 (8.5) 114 (7.4)
Other race/ethnicity 6,363 (4.4) 185 (6.0) 87 (5.7)
Unknown 14,384 (10.0) 359 (11.7) 171 (11.1)
Insurance status
Medicare only 14,315 (9.9) 123 (4.0) 64 (4.2)
Medicare plus Medicaid 7,721 (5.3) 61 (2.0) 24 (1.6)
Medicare plus commercial 40,137 (27.8) 229 (7.5) 107 (7.0)
Medicaid only 24,214 (16.8) 475 (15.5) 219 (14.2)
Commercial only 51,711 (35.8) 2,043 (66.5) 1,049 (68.2)
Uninsured (including self-pay) 4,915 (3.4) 109 (3.5) 59 (3.8)
Unknown 1,494 (1.0) 31 (1.0) 15 (1.0)
Liver disease categories
Viral hepatitis 28,392 (19.6) 448 (14.6) 211 (13.7)
Alcoholic liver disease 16,301 (11.3) 763 (24.9) 391 (25.4)
Autoimmune disorder 15,652 (10.8) 966 (31.5) 518 (33.7)
Metabolic disease 14,344 (9.9) 15 (0.5) 9 (0.6)
Primary sclerosing cholangitis 6,635 (4.6) 118 (3.8) 56 (3.6)
Cancer 4,754 (3.3) 54 (1.8) 29 (1.9)
Primary biliary cirrhosis 864 (0.6) 80 (2.6) 53 (3.5)
Other chronic disease 46,096 (31.9) 349 (11.4) 156 (10.2)
Acute liver failure 11,469 (7.9) 278 (9.1) 114 (7.4)
Severity of illness at diagnosis
None 11,985 (8.3) 179 (5.8) 85 (5.5)
Minimal 33,284 (23.0) 509 (16.6) 246 (16.0)
Moderate 39,719 (27.5) 1,142 (37.2) 564 (36.7)
Severe 27,508 (19.0) 746 (24.3) 367 (23.9)
Maximal 3,615 (2.5) 45 (1.5) 16 (1.0)
Unknown 28,396 (19.7) 450 (14.7) 259 (16.9)
Pennsylvania transplant center N/A 2,758 (89.8) 1,416 (92.1)
Died during study period 57,020 (39.5) 1,027 (33.4) 374 (24.3)
N/A: Not applicable for patients at the diagnosis stage.
∗For the Pennsylvania transplant center, P = .0 1 .F o ra l lo t h e rv a r i a b l e s ,P<. 0 0 1b e c a u s eo ft h el a r g es a m p l es i z e .
3.2. Multivariable Analyses. The adjusted competing
risks models included the primary covariates (gender,
race/ethnicity, and insurance status), all other covariates
mentioned above, interaction terms for diagnosis
and gender, and interaction terms for diagnosis and
race/ethnicity for both the early waiting period and the
later waiting period models. The main eﬀect of insurance
status was nonsigniﬁcant in the later period (after listing),
so interaction terms between diagnosis and insurance were
only included in the model to estimate early waiting times.
Full regression resultsfor the models are provided in Table 3.
Graphs of the ﬁndings for gender, race/ethnicity, and
insurancestatusareshowninFigures1,2,and3,respectively.
The information is analogous to that presented in Table 2 forJournal of Transplantation 5
Table 2: Unadjusted time to listing and time to transplantation, controlling for competing risk of death.
BEFORE LISTING
Total
Cumulative percent of Cumulative percent of
diagnosed patients listed within: diagnosed patients who died within:
1 year 3 years 5 years 8 years 1 year 3 years 5 years 8 years
All diagnosed patients 144,507 1.30 1.82 2.03 2.12 21.91 30.98 35.71 38.56
Gender
Male 77,885 1.43 2.05 2.30 2.40 23.52 32.97 37.82 40.66
Female 66,622 1.15 1.55 1.71 1.79 20.01 28.66 33.26 36.11
Race/ethnicity
White 103,969 1.30 1.85 2.07 2.17 22.87 32.15 37.17 40.20
Black 19,791 0.79 1.11 1.26 1.31 19.17 28.33 32.89 35.60
Hispanic/Asian/other 6,363 1.70 2.52 2.80 2.91 14.27 20.67 23.92 25.65
Unknown 14,384 1.81 2.27 2.44 2.49 22.09 30.76 34.28 36.52
Insurance status
Medicare only 14,315 0.60 0.78 0.81 0.85 32.90 45.57 51.19 53.83
Medicare + Medicaid 7,721 0.52 0.67 0.76 0.79 29.09 41.73 48.26 51.83
Medicare + commercial 40,137 0.42 0.52 0.57 0.57 33.57 46.69 53.82 58.21
Medicaid only 24,214 1.01 1.66 1.86 1.95 13.13 20.56 24.23 26.74
Commercial only 51,711 2.45 3.36 3.7 3.94 14.14 19.78 22.80 24.65
Uninsured (incl. self-pay) 4,915 1.16 1.87 1.99 2.18 11.23 16.38 19.57 21.02
Unknown 1,494 0.94 1.41 1.81 2.01 12.85 18.41 22.09 26.91
AFTER LISTING
Total
Cumulative percent of Cumulative percent of
listed patients transplanted within: listed patients who died within:
1 year 3 years 5 years 8 years 1 year 3 years 5 years 8 years
All listed patients 3,071 36.80 47.80 49.63 50.05 14.23 19.47 20.91 21.26
Gender
Male 1,880 38.88 50.32 52.18 52.50 13.35 18.40 19.79 20.00
Female 1,191 33.50 43.83 45.59 46.18 15.62 21.16 22.67 23.26
Race/ethnicity
White 2,267 37.72 48.83 50.90 51.39 13.94 19.19 20.38 20.87
Black 260 33.08 43.08 43.46 43.85 20.39 26.15 28.85 28.85
Hispanic/Asian/other 185 35.68 45.41 47.03 47.03 11.89 17.84 21.08 21.08
Unknown 359 34.26 45.96 47.35 47.63 12.81 17.27 18.38 18.38
Insurance status
Medicare only 123 40.65 51.22 51.22 52.03 17.07 22.76 24.39 24.39
Medicare + Medicaid 61 34.43 39.34 39.34 39.34 11.48 19.67 21.31 21.31
Medicare + commercial 229 37.99 45.42 46.73 46.73 17.03 24.89 26.64 28.38
Medicaid only 475 33.26 44.00 45.90 46.11 17.26 22.11 24.42 24.84
Commercial only 2,043 37.20 48.80 50.86 51.35 13.22 18.16 19.33 19.53
Uninsured (incl. self-pay) 109 42.20 52.29 53.21 54.13 12.84 17.43 19.27 19.27
Unknown 31 25.81 45.16 48.39 48.39 12.90 19.36 19.36 22.58
the univariable analyses. Of note, in competing risk models,
if the longest noncensored followup time in the observed
data set coincides with a patient death, then the estimated
cumulative incidence function for death (i.e., the competing
risk) converges to 1.0 in the graph. This is the case for all
of the competing risk graphs (right-hand side) in Figure 1
through 3; this artifact is similar to the way in which Kaplan-
Meier graphs show no survivors at the end of the followup
period. Diagnosis-speciﬁc interaction results for gender are
provided in Figure 4.6 Journal of Transplantation
Table 3: Regressions in the multivariable competing risks model with interaction terms.
Diagnosis to listing Diagnosis to death Listing to transplant Listing to death
Variable Beta P-value Beta P-value Beta P-value Beta P-value
Age
18–39 <ref>< ref>
40–64 0.1018 8.70E−02 0.5747 0.00E+00 0.1388 0.11 0.01719 0.89
≥65 −2.181 0.00E+00 0.981 0.00E+00 −0.0751 0.66 0.3803 0.076
Gender
Male <ref>< ref>
Female 0.05282 3.10E−01 −0.2175 0.00E+00 −0.2165 0.0021 0.04415 0.69
Race/ethnicity
White <ref>< ref>
Black −0.7324 5.90E−12 4.14E−02 1.70E−01 −0.115 0.44 0.5058 7.10E−03
Hispanic/Asian/other 0.1405 2.10E−01 −2.90E−01 1.40E−08 −0.2502 0.11 −0.01805 9.40E−01
Unknown 0.1394 7.30E−02 1.35E−02 6.40E−01 −0.2215 0.045 −0.07929 6.50E−01
Insurance status
Medicare only <ref>< ref>
Medicare plus Medicaid −0.411 4.30E−02 0.1222 1.10E−03 −0.2997 0.25 −0.2164 0.54
Medicare plus commercial −0.05088 7.30E−01 −0.004856 8.40E−01 −0.1507 0.41 0.05829 0.8
Medicaid only −0.1287 3.40E−01 0.08097 2.30E−02 −0.1433 0.37 0.03886 0.87
Commercial only 0.6716 2.60E−08 −0.267 0.00E+00 −0.0757 0.6 −0.1517 0.49
Uninsured (including
self-pay)
−0.06924 7.00E−01 −0.1487 1.80E−02 −0.1072 0.61 0.06899 0.82
Severity of illness at diagnosis
None <ref>< ref>
Minimal 0.206 2.00E−02 0.7547 0.00E+00 0.02335 0.85 −0.07078 0.72
Moderate 0.9264 0.00E+00 1.334 0.00E+00 0.02553 0.82 0.002209 0.99
Severe 0.9892 0.00E+00 2.022 0.00E+00 0.01008 0.93 0.1598 0.41
Maximal 0.2154 2.10E−01 2.724 0.00E+00 −0.2741 0.36 1.031 0.0012
Liver diagnoses (ﬁve groups)
(1) (PBC, PSC, ALD, and
autoimmune)
<ref>< ref>
(2) (Viral hepatitis) −0.7455 1.10E−02 −0.2798 5.60E−07 0.06082 0.59 0.1554 0.38
(3) (Acute liver failure) −1.111 6.30E−03 0.3353 4.50E−07 −0.3713 0.04 −0.06777 0.79
(4) (Cancer) −1.959 6.00E−02 0.6301 0.00E+00 −0.2334 0.42 0.1335 0.77
(5) (Metabolic disease,
other)
−1.859 1.30E−08 −0.04497 1.40E−01 −0.2278 0.094 0.1449 0.49
Pennsylvania transplant
center
No N/A <ref>
Yes 0.3121 0.0021 0.5502 0.0011Journal of Transplantation 7
Table 3: Continued.
Diagnosis to listing Diagnosis to death Listing to transplant Listing to death
Variable Beta P-value Beta P-value Beta P-value Beta P-value
INTERACTION TERMS
Diagnosis group × gender
2 × Female −0.1599 1.80E−01 0.006272 8.60E−01 0.05301 0.77 0.2293 0.38
3 × Female 0.459 1.80E−03 0.05483 2.40E−01 0.3382 0.19 0.3079 0.32
4 × Female −0.9512 8.50E−03 −0.1406 5.60E−03 1.218 0.035 −0.2633 0.77
5 × Female −0.2384 6.20E−02 0.004479 8.40E−01 0.07122 0.73 −0.03655 0.9
Diagnosis group ×
race/ethnicity
2 × Black −0.03861 8.30E−01 0.1662 2.80E−04 −0.2849 0.31 −0.2854 0.41
3 × Black 0.243 3.30E−01 −0.06367 3.20E−01 −0.2003 0.64 −0.4171 0.41
4 × Black 0.5954 3.00E−01 0.05434 5.60E−01 0.361 0.73 −0.2571 0.8
5 × Black 0.5146 2.80E−02 0.08273 4.30E−02 −0.3152 0.45 −0.2944 0.53
2 × Hispanic/Asian/other −0.06936 7.40E−01 0.1438 8.20E−02 0.2924 0.34 −0.6491 0.23
3 × Hispanic/Asian/other 0.3302 3.00E−01 0.121 3.50E−01 0.301 0.6 0.9397 0.071
4 × Hispanic/Asian/other 0.5255 2.50E−01 −0.2266 9.30E−02 0.7187 0.12 −8.938 0
5 × Hispanic/Asian/other −0.009698 9.80E−01 0.0801 2.80E−01 −0.9032 0.26 1.197 0.028
2 × Unknown −0.3849 5.30E−02 −0.01653 8.00E−01 0.3819 0.11 −0.8792 0.16
3 × Unknown 0.2203 3.10E−01 0.0593 4.30E−01 −0.8466 0.092 1.048 0.01
4 × Unknown −0.01568 9.70E−01 −0.08379 3.30E−01 −0.1711 0.8 −8.964 0
5 × Unknown −0.07788 7.10E−01 0.01727 6.50E−01 0.5868 0.069 −0.2218 0.66
Diagnosis group × insurance
status
2 × Medicare plus
Medicaid 0.01518 9.70E−01 0.0759 3.30E−01
3 × Medicare plus
Medicaid
−0.2036 7.80E−01 −0.08408 4.70E−01
4 × Medicare plus
Medicaid
−3.869 1.70E−04 −0.1627 2.40E−01
5 × Medicare plus
Medicaid
−0.004049 9.90E−01 0.005655 9.10E−01
2 × Medicare plus
commercial 0.1845 6.20E−01 0.004062 9.50E−01
3 × Medicare plus
commercial 0.4838 3.20E−01 −0.1051 1.70E−01 N/A
4 × Medicare plus
commercial 0.6797 5.50E−01 −0.2542 7.90E−04
5 × Medicare plus
commercial
−0.1228 7.50E−01 −0.04907 1.30E−01
2 × Medicaid only −0.3384 2.90E−01 −0.1179 6.50E−02
3 × Medicaid only 0.1897 6.60E−01 −0.6395 6.20E−15
4 × Medicaid only 0.5077 6.70E−01 0.001579 9.90E−01
5 × Medicaid only 0.2893 4.30E−01 −0.1224 1.20E−028 Journal of Transplantation
Table 3: Continued.
Diagnosis to listing Diagnosis to death Listing to transplant Listing to death
Variable Beta P-value Beta P-value Beta P-value Beta P-value
2 × Commercial only −0.2162 4.70E−01 −0.2046 9.00E−04
3 × Commercial only −0.2264 5.80E−01 −0.274 1.90E−04
4 × Commercial only 0.6286 5.40E−01 −0.1069 2.00E−01
5 × Commercial only −0.2812 4.00E−01 −0.09617 9.70E−03
2 × Uninsured −0.2524 5.40E−01 −0.5278 9.30E−06
3 × Uninsured −0.7369 2.10E−01 −0.5542 1.10E−05
4 × Uninsured 1.552 2.00E−01 −0.5514 1.50E−02
5 × Uninsured 0.4768 3.10E−01 −0.2448 1.10E−02
Abbreviations: PBC-primary biliary cirrhosis; PSC-primary sclerosing cholangitis; ALD-alcoholic liver disease.
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Figure 1: Gender-related results in the adjusted competing risks model.Journal of Transplantation 9
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Figure 2: Race/ethnicity-based results in the adjusted competing risks model.
3.2.1. Gender. In terms of the main eﬀect of gender, early
waitingtimes(fromdiagnosistolisting)weresimilarformen
and women (beta = 0.052, P = .31; Table 3 ), and men were
more likely to die without ever being listed (beta = −0.2175,
P<. 0001).
However, the overall eﬀect of gender on early waiting
time was slightly diﬀerent when the interactions between
gender and diagnosis and the distribution of men and
women in the diagnosis categories were taken into account
(Figure 4). Three diagnosis categories—hepatitis, cancer,
and metabolic diseases—aﬀected 65% of the total cohort,
and larger percentages of women than men were in these
categories. Women in these categories were less likely to be
listed for transplants than were men in the total cohort. As
a result, women experienced slightly longer waiting times in
the early period than men overall, as shown in Figure 1(a).
Later waiting times (from listing to transplant) were
longerfor women, and women were less likely to everreceive
at r a n s p l a n t( b e t a= −0.2165, P = .0021; Table 3 ). Among
patientslistedfortransplantation,thelikelihoodofdeathwas
similar formenandwomen.Thedisease-speciﬁc interactions
did not signiﬁcantly change the overall eﬀectofgenderin the
later period.
3.2.2. Race/ethnicity. In the early period (Figures 2(a) and
2(b)), race/ethnicity continued to be important even after
adjustment for covariates in the multivariable models.
Compared with white patients (the referent group), black
patients waited longer and were less likely to be listed for
transplantation (beta = −0.7324, P<. 0001; Table 3), and
patients in the Hispanic/Asian/other group had substantially
better survival times without listing (beta = –0.29, P<
.0001). The interaction terms indicate that only black
patients with metabolic disorders showed a diﬀerent pattern
from the overall trend in that they tended to be listed sooner
and to die sooner (Table 3).10 Journal of Transplantation
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Figure 3: Insurance-based results in the adjusted competing risks model.
In the later period, the time from listing to trans-
plantation was similar among the racial/ethnic groups and
unaﬀected by the disease-speciﬁc interactions (Figure 2(c)).
In terms of the competing risk (Figure 2(d)), black patients
were more likely than other patients to die on the waiting
list without receiving a transplant. The risks of death
were aﬀected by disease-speciﬁc interactions in that they
were lower for Hispanic/Asian/other patients with cancer
(beta = –8.938, P<. 0001; Table 3), higher for His-
panic/Asian/other patients with metabolic disease (beta =
1.197, P = .028), lower for patients of unknown race with
cancer (beta = −8.964, P<. 0001), and higher for patients
of unknown race with acute liver failure (beta = 1.048, P =
.01).
3.2.3. Insurance Status. Time to listing was similar for
most insurance status groups (Figures 3(a) and 3(b)). The
exceptions were patients with combined Medicare/Medicaid
coverage, who had longer waiting times (beta = −0.411,
P = .0043;Table 3),andpatientswithcommercialinsurance,
who had shorter waiting times (beta = 0.6716, P<. 0001).
Among individuals who were not listed for transplants,
the highest risks of dying were in those with combined
Medicare/Medicaid (beta = 0.1222, P = .0011) and those
with Medicaid alone (beta = 0.0809, P = .023), whereas the
lowest risks of dying were in commercially insured patients
(beta = −0.267, P<. 0001) and uninsured patients (beta =
−0.1487, P = .018). These trends were also apparent in the
disease-speciﬁc interactions, where the lowest risks of dying
were again in commercially insured patients and uninsured
patients (Table 3).
A f t e rl i s t i n g ,t h e r ew a sn ov a r i a t i o nr e l a t e dt oi n s u r a n c e
status: both time to transplant and time to death without
transplant were similar for all payergroups (Figures 3(a)and
3(b)).Journal of Transplantation 11
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Figure 4: Gender-related results in the adjusted competing risks model. Abbreviations: PBC-primary biliary cirrhosis; PSC-primary
sclerosing cholangitis;ALD-alcoholic liver disease.
4.Discussion
Our analyses of a statewide population-based data set for
adults who had liver-related hospitalizations showed that
sociodemographics were associated with variation in early
waiting times (before being listed for transplant) as well
as risk of death. Although the overall experiences were
similar for men and women before listing, there was sub-
stantial variation related to both race and insurance status.
Black patients were less likely to be listed for transplant
upon diagnosis. Insurance status also mattered in the early
period, in terms of both the likelihood of being listed for
transplant and the likelihood of death without ever being
listed. Whereas commercially insured patients tended to do
better, those covered by Medicare/Medicaid combined were
disadvantaged. These patterns may be indicative of disease
progression when patients present with symptoms (in this
case, when patients are hospitalized), but our analyses did
adjust for disease severity at the time of diagnosis.
Once patients are placed on the transplant waiting list,
gender appeared more signiﬁcant as women waited longer to
receive a transplant; black patients were more likely to die12 Journal of Transplantation
on the waiting list without a transplant, but insurance status
played no role in later waiting time diﬀerences. All in all, the
timing diﬀerences were most pronounced before listing, but
were not completely eliminated after listing.
Our study had several limitations that deserve men-
tioning. First, the study depended on hospitalization data
from only one state (Pennsylvania) to identify patients
with transplant potential. Second, although the study linked
information from 5 participating transplant centers, this
information varied across centers in terms of format, detail,
and completeness. As a result, we could only explore
disparities for 2 periods (diagnosis to listing and then listing
to transplant). A more comprehensive analysis of early dis-
parities requires standardizing the data that are collected at
these earlier transitions in the transplantation process prior
to listing (diagnosis to referral, referral to evaluation, and
evaluation to listing). Third, insurance status was based on
theindexhospitalization only;any potentialchanges in payer
information were not observed. Fourth, the study period
predatestheMELDscoring system, thoughitis worth noting
that our main ﬁnding (i.e., that race/ethnicity and insurance
status are associated with variability in early waiting times)
refers to stages of the organ allocation process that are
unaﬀected by MELD. Fifth, given the study’s retrospective
nature and the lack of information about patient preferences
for transplantation, we cannot infer causality.
To our knowledge, our study is the ﬁrst population-
based study of the timing of being listed for transplant
services. Previously, we reported diﬀerences in the overall
likelihood of moving through the allocation and transplant
process [15]. The results of the study reported here conﬁrm
those earlier ﬁndings and provide strong evidence that
socioeconomic factors play a role in access to the stages of
transplant services in which there is no formal oversight.
With the persistent gap between demand for transplant
services and supply of available donor organs, much eﬀort
by policymakers and the transplant community is devoted
to ensuring the fairness of the transplant system. Where
this system is visible and the process is accountable—
namely, after individuals are listed by a transplant center—
researchers have demonstrated marked improvements in
recent years, attributed in part to UNOS oversight and
reforms such as the MELD scoring system. Still lacking,
however, are centralized data sources to accurately measure
the denominator population—that is, the population of
all individuals who have end-stage liver disease and are
potentially eligible for a transplant. Only with these data can
researchers and policymakers measure the true demand for
liver-transplant services, assess the fairness of the process,
and optimize the allocation of available donor organs.
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